ReviewWorld journal of transplantation2025
Current perspectives and guidelines on liver transplantation for metastatic colorectal cancer.
Review in World journal of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common cancer globally, with 20%-25% of patients diagnosed at stage IV, significantly affecting overall survival (OS). Only 14% of stage IV patients survive for 5 years with palliative chemotherapy. However, the role of liver transplantation (LT) in the management of CRC liver metastasis (CRCLM) is an evolving area of interest. Recent advancements in oncologic outcomes and clinical understanding have prompted the re-evaluation of LT as a viable treatment option for CRCLM. A promising result from some prospective pilot studies reported a 5-year OS rate of 60% after LT for patients with CRCLM. Key factors influencing eligibility include tumor biology, absence of extrahepatic disease, and the patient's performance status. By synthesizing the latest research findings, we aim to provide a comprehensive overview that summarizes the most relevant data related to the clinical outcomes of patients who underwent LT for CRCLM. We aim to provide a comprehensive overview by synthesizing the latest research findings. This review discusses the inclusion criteria and eligibility for LT in CRCLM, which are of great importance to patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.